Topic Menu
► Topic MenuTopic Editors



Pharmacogenetics: A Tool in Cancer Therapy
Topic Information
Dear Colleagues,
Over the past years, the availability of high-throughput technologies has led to an important change in pharmacogenetics, improving the practice of precision medicine. The tumour genetic landscape influences treatment response in cancer patients. Multiple molecular mechanisms of resistance to therapies in solid or hematologic tumours have been discussed, highlighting the degree of tumours’ heterogeneity. Multiple approaches, using liquid biopsies, circulating tumour cells and tissue biopsies, can be helpful to monitor patients during therapy and understand drug resistance mechanisms. This knowledge has paved the way for the development of personalized medicine aimed at providing better clinical and therapeutic approaches. To this end, there is an urgent need for the identification of predictive biomarkers of response/resistance to treatments and toxicity, including new tools for genome analysis for the development of personalized medicine. We are pleased to invite you to contribute to our Topic entitled “Pharmacogenetics: A Tool in Cancer Therapy” aimed to collect contributions on the potential role of Pharmacogenetics in cancer treatment, also highlighting the strength as well as its limits in clinical translation. This Topic aims to investigate the different pharmacogenetics approaches useful to identify potential biomarkers in cancer therapy. In this Topic, original research articles and reviews are welcome.
Research areas may include (but are not limited to) the following:
- Genetic variability related to drug toxicity and efficacy in cancer;
- Genomic and proteomic profiling in cancer;
- ncRNA profiles to predict prognosis and outcome in cancer;
- Liquid biopsy in cancer;
- Methylation profiles to predict cancer prognosis and outcome;
- Multi-omics approaches to the study of cancer treatment response;
- Epigenetic changes as determinants of drug response and resistance in cancer;
- Novel genomic targets for drug development.
I/We look forward to receiving your contributions.
Dr. Stefania Crucitta
Dr. Gloria Ravegnini
Dr. Rossana Roncato
Topic Editors
Keywords
- pharmacogenetics
- pharmacogenomics
- target therapy
- cancer therapy
- personalised medicine
- solid tumour
- haematologic tumour
- liquid biopsy
- treatment toxicity
Participating Journals
Journal Name | Impact Factor | CiteScore | Launched Year | First Decision (median) | APC |
---|---|---|---|---|---|
![]()
Cancers
|
4.5 | 8.0 | 2009 | 17.4 Days | CHF 2900 |
![]()
International Journal of Molecular Sciences
|
4.9 | 8.1 | 2000 | 16.8 Days | CHF 2900 |
![]()
Journal of Personalized Medicine
|
- | 4.1 | 2011 | 17.4 Days | CHF 2600 |
![]()
Onco
|
- | - | 2021 | 27.8 Days | CHF 1000 |
![]()
Pharmaceuticals
|
4.3 | 6.1 | 2004 | 13.9 Days | CHF 2900 |
Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.
MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:
- Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
- Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
- Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
- Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
- Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.